Article
Oncology
Jie-Ru Yang, Ju Wang, Hai-Ming Li, Shuai Gao, Yu-Chen Fan, Kai Wang
Summary: The study found that the IL-6 promoter methylation level is significantly lower in patients with HBV-associated hepatocellular carcinoma, and it is independently associated with the development of liver cancer. The combined use of IL-6 methylation level and AFP can improve the diagnostic accuracy of liver cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shanting Ye, Yong Ni
Summary: The study revealed that upregulated SNHG9 in HCC is associated with shorter disease-free survival, and knocking down SNHG9 can inhibit cell proliferation, block cell cycle progression, and suppress cell migration and invasion by upregulating GSTP1.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Anne Olbrich, Olga Gros, Sebastian Ebel, Timm Denecke, Holger Goessmann, Nicolas Linder, Florian Lordick, Dirk Forstmeyer, Daniel Seehofer, Robert Sucher, Sebastian Rademacher, Johannes Niemeyer, Madlen Matz-Soja, Thomas Berg, Florian van Boemmel
Summary: This study investigated the association between circulating Dickkopf-related protein 1 (DKK-1) and baseline characteristics as well as response to transarterial chemoembolization (TACE) in European HCC patients. The results showed that DKK-1 levels were strongly associated with liver cirrhosis, tumor size, and Barcelona Clinic Liver Cancer stages. DKK-1 levels could better identify responders to TACE, especially in patients with low AFP levels.
Article
Cell Biology
Lixu Zhu, Wenzhi Guo
Summary: This study identified the methylation characteristics of PD-1-negative HCC samples and proposed a prognostic model based on DMEGs. The tumor samples showed significantly lower ESTIMATE scores compared to normal samples, and 31 DMEGs were identified as able to distinguish PD-1-negative samples from normal samples. Functional enrichment analysis revealed the involvement of these genes in tumor-related and immune-related pathways, and potential therapeutic drugs were identified through DrugBank screening. The prognostic model based on three DMEGs demonstrated good predictive power for HCC prognosis and was validated in an independent cohort.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Peng Huang, Mengxiang Xu, Haijun Han, Xinyi Zhao, Ming D. Li, Zhongli Yang
Summary: DNA methylation plays a crucial role in regulating gene expression in hepatocellular carcinoma (HCC). This study identified a large number of differentially methylated CpG sites in HCC and highlighted the activation of cell cycle-related pathways and repression of metabolic pathways.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ganji Purnachandra Nagaraju, Begum Dariya, Prameswari Kasa, Sujatha Peela, Sujatha Peela Bassel F. El-Rayes
Summary: HCC is the most common primary malignancy of the liver, with a high fatality rate. Genetic and epigenetic aberrations are commonly observed in HCC, including chromatin remodeling, histone alterations, DNA methylation, and ncRNA expression. In-depth understanding of the epigenetics of HCC is critical for developing rational clinical strategies, improving overall survival, and predicting therapeutic outcomes.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Cell Biology
Lixu Zhu, Wenzhi Guo
Summary: This study identified the methylation characteristics of PD-1-negative HCC samples and potential therapeutic drugs, and proposed a prognostic model based on UBD, CD5L, and CD213A2 methylation expression.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Junhai Pan, Duguang Li, Xiaoxiao Fan, Jiaxi Cheng, Shengxi Jin, Peng Chen, Hui Lin, Yirun Li
Summary: This study used MassARRAY EpiTYPER technology to investigate the methylation differences of DLC1 in HCC tissues and adjacent noncancerous tissues, and explored the functional correlation between epigenetic modifications and DLC1 gene regulation using modified CRISPR-Cas9 system and DNMTi. The methylation levels of DLC1 isoforms in HCC samples were significantly lower than those in adjacent noncancerous tissues, and the expression of DLC1 could be bidirectionally regulated. Hypomethylation of DLC1 in HCC samples was associated with satellite lesions and incomplete tumor capsule. DLC1 methylation levels could be used as a potential biomarker for HCC.
DNA AND CELL BIOLOGY
(2023)
Review
Oncology
Yan Li, Yuanyuan Zheng, Liwei Wu, Jingjing Li, Jie Ji, Qiang Yu, Weiqi Dai, Jiao Feng, Jianye Wu, Chuanyong Guo
Summary: The traditional method of tumor biopsy for hepatocellular carcinoma is limited and there is a need for a novel non-invasive diagnostic technique; circulating tumor DNA technology provides an important method for cancer screening, diagnosis, treatment selection, and prognosis prediction in hepatocellular carcinoma.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Obstetrics & Gynecology
Yuan-Hada He, Rui-Jun Su, Jian Zheng
Summary: Methylation of DKK-1 gene promoter in cervical exfoliated cells of patients with CSCC is associated with high-risk HPV infection and various clinicopathological factors. The methylation degree of DKK-1 gene is not correlated with the type of high-risk HPV infection. Detection of DKK1 gene methylation combined with HPV may improve sensitivity, specificity, and accuracy in diagnosing CSCC, potentially serving as a non-invasive screening method.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2021)
Article
Gastroenterology & Hepatology
Wu Xing, Peng-Cheng Zhou, Hao-Ye Zhang, Li-Min Chen, Yang-Mei Zhou, Xue-Fei Cui, Zhen-Guo Liu
Summary: The study revealed that circ_GLIS2 suppresses the growth and metastasis of HCC by inhibiting cell proliferation, migration, and invasion, while promoting cell apoptosis. This suggests that circ_GLIS2 could potentially serve as a diagnostic marker or therapeutic target for HCC.
LIVER INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Jiaxiu Ma, Jiapei Jin, Huishuang Lu, Jin Zhang, Yalan Li, Xuefei Cai
Summary: This study investigated the role of EXO1 in HCC as a potential diagnostic and prognostic biomarker. The expression of EXO1 was found to be significantly higher in HCC tissues and serums compared to controls. EXO1 expression levels were associated with immune cell infiltration, immune checkpoint genes, and TP53 in HCC tissues. DNA methylation changes in the EXO1 gene were also associated with HCC prognosis. Cox regression analysis showed that EXO1 was an independent risk factor for the overall survival and disease-specific survival of HCC patients. EXO1 expression levels accurately distinguished HCC tissues from normal liver tissues. These findings suggest that EXO1 could be a promising therapeutic target in HCC.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Microbiology
Miao Liu, Lingyao Du, Xing Cheng, Man Yuan, Jin Shang, Ying Shi, Hailing Yang, Hong Tang
Summary: This study revealed that the expression of SOCS-1 is decreased in HCV-HCC tissues, and that higher HCV viral load is associated with lower SOCS-1 expression. It was also found that HCV infection can upregulate the methylation of the SOCS-1 gene, which may contribute to the downregulation of SOCS-1 in HCV-infected tissues and cell lines. These findings provide insights into the mechanism of HCV-induced hepatocellular carcinoma.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yusha Xiao, Kang Yang, Pengpeng Liu, Dong Ma, Ping Lei, Quanyan Liu
Summary: The study showed that DNASE1L3 could inhibit the progression of HCC by inducing cell apoptosis and weakening glycolysis, suggesting its potential as a prognostic biomarker and therapeutic target for HCC.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Junye Liu, Lulu Xia, Shilei Wang, Xuefei Cai, Xiaoli Wu, Chunhong Zou, Baoju Shan, Miao Luo, Deqiang Wang
Summary: The study revealed the important role of E2F4 in hepatocellular carcinoma (HCC), promoting cancer cell proliferation, migration, and invasion, and potentially serving as a biomarker for HCC.